XML 54 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING AND REPORTABLE SEGMENTS
 9 Months Ended
Sep. 30, 2013
Segment Reporting [Abstract]  
Operating and Reportable Segments
OPERATING AND REPORTABLE SEGMENTS

The Company's operating and reportable segments, “Infusion Services," "Home Health Services” and “PBM Services,” reflect how the Company's chief operating decision maker reviews the Company's results in terms of allocating resources and assessing performance.

The Infusion Services operating and reportable segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment, products and services. Infusion services include the dispensing and administering of infusion-based drugs, which typically require additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home infusion services also include the dispensing of certain self-injectable therapies.

The Home Health Services operating and reportable segment provides services including the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home.

The PBM Services operating and reportable segment consists of integrated pharmacy benefit management ("PBM") services, which primarily consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. Under these discount programs, individuals who present a discount card at any of the Company's participating network pharmacies receive prescription medications at a discounted price compared to the retail price.

The Company's chief operating decision maker evaluates segment performance and allocates resources based on Segment Adjusted EBITDA. Segment Adjusted EBITDA is defined as income (loss) from continuing operations, net of income taxes adjusted for net interest expense, income tax expense (benefit), depreciation, amortization of intangibles and stock-based compensation expense and prior to the allocation of certain corporate expenses. Segment Adjusted EBITDA excludes acquisition, integration, and transitional expenses; restructuring expense; and other expenses related to the Company's strategic assessment. Segment Adjusted EBITDA also excludes the operating losses of start-up branch locations that the Company has invested in organically rather than through acquisition. Segment Adjusted EBITDA is a measure of earnings that management monitors as an important indicator of operating and financial performance. The accounting policies of the operating and reportable segments are consistent with those described in the Company's summary of significant accounting policies.



Segment Reporting Information
(in thousands)
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2013
 
2012
 
2013
 
2012
Results of Operations:
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
Infusion Services - product revenue
$
169,011

 
$
123,361

 
$
469,594

 
$
338,721

Infusion Services - service revenue
5,791

 
2,575

 
15,750

 
7,242

Total Infusion Services revenue
174,802

 
125,936

 
485,344

 
345,963

 
 
 
 
 
 
 
 
Home Health Services - service revenue
18,071

 
17,299

 
54,240

 
50,870

 
 
 
 
 
 
 
 
PBM Services - service revenue
16,006

 
27,130

 
59,099

 
85,066

 
 
 
 
 
 
 
 
Total revenue
$
208,879

 
$
170,365

 
$
598,683

 
$
481,899

 
 
 
 
 
 
 
 
Adjusted EBITDA by Segment before corporate overhead:
 
 
 

 
 
 
 

Infusion Services
$
14,693

 
$
9,931

 
$
41,201

 
$
25,740

Home Health Services
567

 
1,402

 
2,547

 
3,557

PBM Services
4,278

 
6,905

 
15,397

 
19,367

Total Segment Adjusted EBITDA
19,538

 
18,238

 
59,145

 
48,664

 
 
 
 
 
 
 
 
Corporate overhead
(7,483
)
 
(6,625
)
 
(23,531
)
 
(19,665
)
 
 
 
 
 
 
 
 
Interest expense, net
(7,182
)
 
(6,497
)
 
(20,168
)
 
(19,705
)
Loss on extinguishment of debt
(15,898
)
 
—

 
(15,898
)
 
—

Income tax benefit
587

 
2,506

 
31

 
2,644

Depreciation
(3,269
)
 
(2,134
)
 
(8,298
)
 
(6,115
)
Amortization of intangibles
(1,009
)
 
(1,087
)
 
(4,801
)
 
(2,844
)
Stock-based compensation expense
(1,427
)
 
(1,687
)
 
(7,260
)
 
(4,398
)
Acquisition and integration expenses
(4,890
)
 
(998
)
 
(13,025
)
 
(1,806
)
Restructuring and other expenses and investments
(1,409
)
 
(2,321
)
 
(4,424
)
 
(3,696
)
Loss from continuing operations, net of income taxes
$
(22,442
)
 
$
(605
)
 
$
(38,229
)
 
$
(6,921
)
 
 
 
 
 
 
 
 
Supplemental Operating Data
 

 
 

 
 
 
 
 
 
 
 
 
September 30,
2013
 
December 31,
2012
Total Assets:
 

 
 

 
 
 
 
Infusion Services
 
 
 
 
$
776,878

 
$
438,623

Home Health Services
 
 
 
 
63,402

 
62,403

PBM Services
 
 
 
 
32,363

 
36,354

Corporate unallocated, including cash and cash equivalents
 
 
 
 
53,641

 
95,813

Assets associated with discontinued operations, not sold
 
 
 
 
16

 
9,183

Total
 
 
 
 
$
926,300

 
$
642,376